Exploring Okra-Derived Compounds as Prospective Aromatase Inhibitors: A Computational Study for Enhanced Breast Cancer Therapy

Breast cancer with estrogen receptor positivity represents itself as the most prevalent malignancy among postmenopausal women. One of the promising therapeutic approach involves the use of Aromatase Inhibitors, which competitively bind to aromatase, reducing estrone and estradiol levels. While current drugs have improved survival rates, they are not without adverse effects. Consequently, this study explores the computational screening of medicinally relevant compounds derived from Okra for potential Aromatase Inhibition. Molecular Docking, employing AMDock v1.5.2, was utilized to assess binding affinities with aromatase (PDB:3EQM). Subsequently, in-depth molecular interactions were examined using Discovery Studio Visualizer v4.5, and the stability of docked complexes was evaluated via Molecular Dynamics with the GROMACS package, focusing on RMSD, RMSF, H-bond count, and SASA. The pharmacokinetic properties of the Okra compounds were predicted using admetSAR v2.0. Our findings highlight Quercetin 3-gentiobioside as a standout candidate, demonstrating superior binding affinity (-10 kcal/mol) and an Estimated Ki of 46.77 nM compared to Letrozole and other Okra compounds. Molecular dynamics analysis confirms the stability of Quercetin 3-gentiobioside binding in terms of H-bonds and conformational integrity. In conclusion, our computational investigation identifies Quercetin 3-gentiobioside, along with Quercetin 3-O-rutinoside and Hyperin, as promising candidates for preclinical studies in the pursuit of potential Aromatase Inhibitors.